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Despite decades of research, the highly prevalent pregnancy complication preeclampsia,
“the disease of theories,” has remained an enigma. Indeed, the etiology of preeclamp-
sia is largely unknown. A compiling amount of studies indicates that the pathological
basis involves a complex array of genetic predisposition and immunological maladapta-
tion, and that a contribution from the mother, the father, and the fetus is likely to be
important. The Human Leukocyte Antigen (HLA)-G is an increasing focus of research in
relation to preeclampsia. The HLA-G molecule is primarily expressed by the extravillous
trophoblast cells lining the placenta together with the two other HLA class Ib molecules,
HLA-E and HLA-F. Soluble isoforms of HLA-G have been detected in the early endometrium,
the matured cumulus–oocyte complex, maternal blood of pregnant women, in umbilical
cord blood, and lately, in seminal plasma. HLA-G is believed to be involved in modulating
immune responses in the context of vascular remodeling during pregnancy as well as in
dampening potential harmful immune attacks raised against the semi-allogeneic fetus. In
addition, HLA-G genetic variants are associated with both membrane-bound and soluble
forms of HLA-G, and, in some studies, with preeclampsia. In this review, a genetic contri-
bution from the mother, the father, and the fetus, together with the presence and function
of various immune cells of relevance in pregnancy are reviewed in relation to HLA-G and
preeclampsia.
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INTRODUCTION
Preeclampsia is believed to develop in two stages: a pre-clinical
stage without symptoms typically characterized by poor placen-
tation, and a clinical stage occurring some point after 20 weeks
of gestation with symptoms of increased blood pressure accom-
panied by proteinuria. Subclinical changes include placental
oxidative stress and endothelial activation.
A unique subset of cytokine-producing decidual NK (dNK)
cells is identified in the placenta during pregnancy. In contrast to
the conventional NK cells of the periphery (pNK), which make up
5% of the peripheral leukocyte population, dNK cells are enriched
in the placental compartment constituting up to 75% of the pla-
cental leukocyte population (1, 2). dNK cells are known to produce
angiogenetic factors, and the poor trophoblastic vascular remod-
eling of the spiral arteries in preeclampsia has been attributed a
decrease in dNK cell numbers and/or abrogated functions. More-
over, T and NK cells of the periphery are known to be activated in
preeclampsia (3).
The human Major Histocompatibility Complex (MHC) is a
large gene family located on chromosome 6. It includes the classi-
cal Human Leukocyte Antigen (HLA) class Ia and II genes (HLA-A,
-B, -C, -DR, -DQ, and -DP). These genes and molecules are well
known for their importance in antigen-peptide presentation and
in organ transplantation, and for their association with a range
of diseases, especially autoimmune diseases (4, 5). However, the
MHC region also includes the so-called non-classical HLA class
Ib genes: HLA-E, -F, and -G (6–9). The role of these genes and
molecules in pregnancy and in preeclampsia is a main focus of
this review.
There are two anatomical contact-points between the mater-
nal immune cells and the fetus: the systemic immune response
between maternal circulating immune cells and the syncytiotro-
phoblasts, and the local immune response between decidual
immune cells and the extravillous trophoblast cells (Figure 1) (10).
The syncytiotrophoblast cells are devoid of HLA I molecules (11),
and it is unlikely that T cell responses are directed against these.
Protection from NK lysis is provided by the non-classical HLA
class Ib molecules, HLA-E and HLA-G, which are highly expressed
in extravillous trophoblast cells lining the placenta, and possibly
also expressed by syncytiotrophoblast cells (12, 13). However, in
addition to expressing the HLA class Ib molecules, extravillous
trophoblast cells express low amounts of the polymorphic HLA-
C, which could serve as a source of allorecognition by maternal
immune cells.
HLA CLASS Ib IN PREGNANCY
Human trophoblast cells express one HLA class Ia molecule (HLA-
C) and all HLA class Ib molecules (HLA-E, -F, and -G) (6, 12, 14).
Considering the unique co-expression of HLA-E, -F, and -G in the
placenta and their mutual involvement in immune modulation,
a combined effect or interaction of all three class Ib molecules
would not seem far stretched to hypothesize (12). HLA-G has
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FIGURE 1 |The feto-maternal interface. The extravillous trophoblast cells
invades the maternal decidua and the spiral arteries, possibly remodeling
these in order to increase blood flow to the fetus as pregnancy progresses.
HLA-G and HLA-E protect invading trophoblast cells from lysis by NK cells
throughout pregnancy, while HLA-F is expressed on the surface of
extravillous trophoblast cells at later stages.
been intensively studied, HLA-E moderately studied, while little
is known about HLA-F. Nonetheless, some studies on the expres-
sion and function exist, and can be related to their possible role in
pregnancy.
Human leukocyte antigen-G is strongly expressed throughout
pregnancy, both in the cytoplasm of extravillous trophoblast cells
and on the cell surface (15, 16). HLA-F is weakly expressed in
the extravillous trophoblast during the first trimester of preg-
nancy (16). From second trimester and on, the expression increases
continuously and HLA-F translocates to the cell surface. HLA-E
expression is similar to HLA-F, but HLA-E is additionally found
on the cell surface in the first trimester. The increase in HLA-E and
HLA-F expression coincides with fetal growth (16), and implies a
role, at least for HLA-F, in this context.
Unlike classical HLA Ia molecules, the primary role of HLA-G
is not antigen presentation, but rather immune regulation through
the receptors ILT2, ILT4, and KIR2DL4 (Figure 2) (17–19). HLA-E
mRNA has been detected in all cells and tissues examined and its
function is likely to extend that of pregnancy (20). In contrast to
HLA-G, HLA-E has been demonstrated to present antigens to a
restricted subset of T cells (21), and in addition, to act as a lig-
and for the NK-specific CD94/NKG2 lectin receptors that regulate
the activity of these cells (Figure 2) (22, 23). In the placenta, lig-
ands for HLA-E are restricted to leader peptides from HLA-G and
HLA-C, partly because of its hydrophobic properties, which limit
the selection of peptides it can bind (24).
The functional role of HLA-F is the least defined. HLA-F is not
believed to act in antigen presentation as it is expressed on the
surface of proliferating viral-transformed lymphoid and mono-
cyte cells without bound peptide (25, 26), and sometimes found
associated with other HLA class I molecules also devoid of pep-
tide as open conformers (27). The functional relevance of open
HLA class I conformers is unclear, but it is possibly related to their
unusual ability to cis-associate with themselves and other receptors
(28). At least some studies indicate that these forms enable them
to act as regulators of ligand–receptor interactions (28). Interest-
ingly, similarly to HLA-G, HLA-F tetramers are able to bind ILT2
and ILT4 (Figure 2) (29).
HLA-G GENE AND HLA-G mRNA AND PROTEIN ISOFORMS
Eighteen HLA-G alleles have been described at the protein level
according to the WHO Nomenclature Committee for Factors of
the HLA System and the International Immunogenetics Infor-
mation System (IMGT)/HLA Database. HLA-G exhibits low
nucleotide variability in the coding regions. Most HLA-G poly-
morphisms do not alter the amino acid sequence, and are not
expected to affect secondary structures of the heavy chains. HLA-
G is alternatively spliced to produce seven mRNA isoforms, four
of which encode membrane-bound protein isoforms (HLA-G1,
-G2, -G3, and -G4) and three that encode soluble protein iso-
forms (HLA-G5, -G6, and -G7) (30–34). HLA-G1 represents the
full-length isoform. HLA-G2 results from the removal of exon 3.
HLA-G3 results from the removal of exon 3 and 4, and HLA-
G4 from out-splicing of exon 4. HLA-G5 and -6 are soluble
isoforms due to inclusion of intron 4 in the mature mRNA,
which leads to secreted proteins with additional 21 amino acids
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FIGURE 2 | HLA class Ib and cognate receptors expressed on decidual immune cells.
encoded by the intron 4 sequence (31). HLA-G7 includes exon
2 and part of intron 2, and is predicted to encode a small
soluble isoform, however, more studies are needed to demon-
strate the presence of this isoform in vivo (34). With relevance
for pregnancy, HLA-G4 and -7 mRNAs are not abundant in
placentas (35).
Human leukocyte antigen-F and HLA-E have, like their coun-
terpart, a low degree of polymorphism (36, 37). Compared to
HLA-G and -E, HLA-F is distinguished in the literature by lacking
exon 7, which produces a protein with a shortened cytoplasmic
domain. However, HLA-G also lacks exon 7, and a newer interpre-
tation of the intron and exon nomenclature of the HLA-G gene is
currently receiving attention.
SOURCE OF HLA CLASS Ib AND CELLULAR LOCALIZATION IN
THE PLACENTA
Soluble HLA-G in the maternal circulation is predominantly pro-
duced and shed from trophoblast cells during pregnancy, but a
quantity of sHLA-G is possibly produced by regulatory T cells and
antigen-presenting cells like monocytes and dendritic cells (DCs)
derived hereof (14, 38, 39). In non-pregnant individuals, sHLA-G
likely reflects expression from monocytes (40, 41). Other tissues
or biological fluids where HLA-G has been detected include the
matured cumulus–oocyte complex, thymus, follicular fluid, and
seminal plasma; furthermore at immune privileged sites, HLA-G
expression has been confirmed to the eye, brain, testis, the epi-
didymis, and the prostate gland (42–46). Also, HLA-G is secreted
by erythroblasts (47), which is interesting as increased fetal ery-
throblastosis is detected in women who subsequently develop
preeclampsia (48).
Human leukocyte antigen-E mRNA expression has been
detected in virtually all cells and tissues examined and is expressed
on the surface of a wide variety of cells (20).
Cellular localization of HLA-F is verified in the placenta (12),
the tonsils, spleen, bladder, skin, thymus tissue, and liver cell lines
(25, 49). While surface expression is absent in most tissues (25),
surface expression has been demonstrated on trophoblast cells
during later stages of gestation (12).
Human leukocyte antigen-G mRNA transcripts have been
detected in first trimester and at term in extravillous (12, 15) and in
syncytiotrophoblast cells (12), in the latter case, only mRNA tran-
script encoding the non-membrane forms have been confirmed
(12). Because HLA-G is highly homologous to other HLA class I
molecules, specific antibodies have been difficult to develop (50),
and the protein expression of soluble HLA-G isoforms by syn-
cytiotrophoblast cells cannot be ruled out, as sporadic patches
with HLA-E expression have been detected in this trophoblast cell
fraction (12, 13), which probably requires availability of leader
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peptides from HLA-G. Thus, the exact HLA-G expression profile
in the syncytiotrophoblast cells is still a controversial issue.
In the placental choriocarcinoma cell line JEG-3, a physical
co-localization of HLA class Ib was evidenced, showing HLA-E,
-G, and -C on the cell surface, while HLA-F expression was con-
fined to the cytoplasm (51). Also, using cell bio-imaging, a recent
study revealed that HLA-G and HLA-E are co-localized in preim-
planted embryos (52), indicating a prerequisite for co-expression
of HLA class Ib molecules, which also could apply in the uterine
compartment.
HLA-G CONFORMATIONAL VARIANTS AND HIGH
MOLECULAR WEIGHT COMPLEXES
A recombinant HLA-G protein consisting of the α1 and α2
domains was synthesized to mimic the extracellular part of HLA-
G2 and HLA-G6 in one study (53). It showed that this HLA-G
protein bound ILT4, but not ILT2, and was the first to report a
binding of a HLA-G receptor with truncated HLA-G isoforms. In
continuation of these findings, it was demonstrated that the same
structure is able to induce tolerance and prolong the endurance of
skin allografts in B6-mice and in an ILT4-transgenic mouse model
(53).
In one study, HLA-G5 was hypothesized to indirectly regu-
late trophoblast invasion by binding to decidual leukocytes and
inducing cytokine production, and as a consequence positively
affect placentation (54). More specifically, recombinant HLA-G5
(rHLA-G5) was demonstrated to stimulate trophoblast invasion
upon binding to KIR2DL4 and ILT2, which led to activation of
the ERK pathway via phosphorylation of ERKs (54). Accord-
ingly, trophoblast invasion was reversed with blocking antibodies
for ILT2 and KIR2DL4 (54). Since insufficient trophoblast inva-
sion is a characteristic of preeclampsia, it would be interesting
if further studies of the effects of HLA-G5 on placentation were
performed.
Recently, high molecular weight HLA-G complexes circulating
in exosomes were identified (55). Trophoblast-derived exosomes
are endocytic nanoparticles (<100 nm) shed from the placenta
into the circulation, where they may stimulate or inhibit periph-
eral immune cells, while simultaneously expose paternal antigens
systemically (56). Interestingly, the HLA-G complexes reported
in exosomes were heterogeneous in nature, some proteins corre-
sponding to ubiquitinated HLA-G, while other structures exhib-
ited unclassified protein modifications (55). HLA-G protein alter-
ations may affect quantification in biological fluids. Indeed, solu-
ble HLA-G is readily detected in EDTA-stabilized blood plasma
using a specific ELISA and the MEM-G/9 antibody, while the
detection level is decreased in heparin-stabilized blood plasma
and in serum samples (own unpublished observations). This may
have important implications for detection of sHLA-G and possi-
bly sHLA-E in the circulation of preeclamptic women, specifically
when assessing their potential as biomarkers, and could explain
some of the discrepancies in soluble levels previously described
between studies.
Human leukocyte antigen-G exists in different forms,commonly
as a monomer associated with or without the β2m-subunits or
as hetero- or homodimers, but unique trimeric and oligomeric
forms have also been acknowledged (57–59). The physiological
significance of different forms remains unclear. Recent reports
have demonstrated that β2m-associated HLA-G monomers com-
prise the majority of all HLA-G forms expressed by trophoblast
cells (53), but a significant fraction exists in the form of HLA-
G homodimers by forming an intermolecular disulfide bridge
between two cysteine residues of the α1 domains of two HLA-
G molecules (60). So far, the homodimer form has shown to
be the most active arrangement with a higher affinity for ILT2
and ILT4 compared with the monomer (18). Furthermore, the
homodimer enhances the ILT2-mediated signaling at the cellular
level (18). Interestingly, in trophoblast cell lines, cell bio-imaging
showed that app. 40% of HLA-E and HLA-G are co-localized in
the form of tetramers or higher-order homodimer clusters (51,
52) and that HLA-E and -G form heterotypic associations with
HLA-C (51), indicating a physical association on the cell surface in
higher-order complexes. If these findings reflect a co-dependency
of HLA-E and -G surface expression and co-localization, then a
possibly reduced level of HLA-G in preeclampsia – in addition to
reducing availability of leader peptide necessary for stable HLA-E
surface expression – could also affect the functionality of HLA-E
by other means.
Similar to HLA-G, HLA-F exists with and without association
with β2m, and can form homodimers as well as associate with
other HLA class I (25, 26). The possibility that HLA-F heavy chains
have hidden functions that are determined by the amino acid
sequence of the α domains is plausible (28) and should be investi-
gated in relation to receptor–ligand interactions in pregnancy and
preeclampsia.
HLA-G IN PREGNANCY AND PREECLAMPSIA
Elevated levels of sHLA-G have been observed in the maternal
circulation during pregnancy (61–64). An association between
HLA-G and preeclampsia is supported by several findings. First,
a direct association between reduced HLA-G expression in term
placentas and preeclampsia has been demonstrated with in situ
hybridization, immunohistochemistry on frozen sections, and
with a ribonuclease protection assay (65–67). Second, circulating
sHLA-G levels are decreased in preeclampsia, and in some cases
this is observed as an early event in pregnancy in women who
subsequently develop preeclampsia compared with women with
uncomplicated pregnancy (62, 64, 68–70). Third, HLA-G poly-
morphisms have been associated with sHLA-G levels in peripheral
blood from blood donors and with HLA-G protein expression
in the placenta during pregnancy (71, 72), and fourth, HLA-G
polymorphisms, some of which are associated with circulating
levels, are further associated with increased risk of preeclamp-
sia in some studies (73–76) but not in all (77–80). While the
beneficial role of HLA-G is recognized in relation to pregnancy,
a precise relationship between HLA-G and preeclampsia needs
further appraisal.
FUNCTIONAL SIGNIFICANCE OF HLA-G ISOFORMS IN
RELATION TO PREGNANCY AND PREECLAMPSIA
To emphasize the function of HLA-G in relation to pregnancy
and preeclampsia, several questions need to be addressed. First,
which cells express cognate receptors and what is their function,
second, does HLA-G exhibit isoform-specific functions, and third,
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what molecular structures can HLA-G form, and could it have
functional relevance?
ILT2 and ILT4 are the major receptors for HLA-G. Since ILT2
and ILT4 are expressed by leukocytes – the former by most leuko-
cytes, and the latter primarily by monocytes, macrophages, and
DCs – most attention has been drawn to the interaction between
HLA-G and immune cells (81). However, novel functions of HLA-
G have been suggested, possibly in the context of vascular events
during placentation. Indeed, both ILT2 and ILT4 have been iden-
tified in the mesenchyme of term placentas, but with different
localization. ILT2 was abundant in stromal cells, while ILT4 was
prominent in perivascular smooth muscles. Interestingly, tro-
phoblast cells express neither receptor (82). This is consistent with
recent findings showing that HLA-G5 dimers engage with ILT4
in airway smooth muscle (83). Although ILT2 may be the major
binding protein for leukocytes, ILT4 has been suggested as the
main receptor for HLA-G. Additionally supporting an alternative
role of HLA-G is the observation that CD160, an sHLA-G1 recep-
tor found on endothelial cells but not reported on trophoblast
cells, inhibits angiogenesis by an apoptotic pathway (84).
Arguments for existence of HLA-G-isoform-specific func-
tions include the observation that HLA-G2 and -G6 isoforms
are expressed exclusively in the extravillous trophoblast cells
distal to the villous, while HLA-G5 is ubiquitously expressed
in syncytiotrophoblast cells (85, 86) and maternal blood (62).
The major isoform-specific distinction supported by experimen-
tal studies is based on a functional concentration-dependency,
which implicates HLA-G5 as a potentially more effective stim-
ulator according to some studies (59, 87). HLA-G5 expression
in the placenta seems to be sparse, at least at the mRNA level
(50, 88, 89). Moreover, an isoform-specific role for HLA-G5 in
relation to pregnancy was indicated in a recent study where
HLA-G5 – while low or completely absent in maternal blood
at term in normal pregnancies – was significantly increased in
preeclampsia (62).
On the other hand, an argument for similar functions between
different HLA-G isoforms is given by studies that describe
women who are homozygous for the HLA-G*01:05N null allele
(597DeltaC) and thereby lack expression of HLA-G1 and -G5.
However, they have demonstrable HLA-G levels in the placenta
and produce viable offspring, which is consistent with the idea
that other isoforms – or other HLA class Ib molecules – provide
functional compensation (90).
Most studies correlating circulating sHLA-G levels with
preeclampsia have focused on the HLA-G1 and -G5 isoforms,
which are nearly identical. Soluble HLA-G1 is derived from the
full-length membrane-bound isoform containing a transmem-
brane cytoplasmic region, which may be cleaved by metallopro-
teases and shed from the cell surface (91, 92).
The soluble isoform HLA-G5 is generated due to a stop codon
in intron 4 that prevents translation of the transmembrane cyto-
plasmic domain. Due to technical challenges, HLA-G5 has long
been difficult to identify with specific monoclonal antibodies, but
this issue seems lately to have been overcome (62). One argument
for focusing on HLA-G1 is that it represents the most abundant
isoform in the placenta. However, a functional distinction among
HLA-G isoforms is plausible.
Human leukocyte antigen-G1 is by far the most abundant
HLA-G mRNA isoform, both in preeclamptic placental biopsies
and control placental biopsies, followed by G3, G5, G2, and G6
(35, 88). HLA-G4 and -G7 mRNA transcripts are not abundant
in placentas (35). An in vitro functional study showed that the
truncated isoforms G2, G3, and G4 are expressed on the surface
of transfected cells and protect against NK and T cell-mediated
cytotoxicity (93), and more recently a transfection study showed
that HLA-G1 and HLA-G3 differentially increased HLA-E surface
expression (94), indicating that the less abundant HLA-G isoforms
are able to functionally compensate for HLA-G1 but with different
effectiveness. However, low transcript abundance and/or protein
expression in the placenta has prompted researchers to assume
that these transcripts are less relevant, and in vivo relevance is
typically only supported for G1 and G5. Interestingly, a study
found that the HLA-G mRNA profile in term placental biopsies
is shifted toward a higher frequency of HLA-G5 in preeclamp-
sia (35), which is supported by higher HLA-G5 protein levels in
maternal blood in preeclampsia compared to controls according
to another, independent study (62).
HLA-G POLYMORPHISMS LINKED TO PREECLAMPSIA
A 14 bp insertion/deletion (ins/del) HLA-G polymorphism in the
3′ untranslated region (3′UTR) first described by Harrison et al.
(95), is the best studied HLA-G polymorphism and has shown
to influence HLA-G mRNA transcript size and stability (31, 88,
96–98).
Preeclampsia is a pregnancy condition unique to humans (99).
The HLA-G 14 bp deletion allele is also unique to humans (100),
and interestingly, this allele is more prevalent than the insertion
allele (101, 102), raising the question whether the 14 bp deletion
variant evolved evolutionary as a compensatory mechanism to
counter pathological conditions only seen in humans. It is an
intriguing thought that this theory could apply to preeclampsia.
Several studies have been undertaken in effort to clarify,
whether the fetal HLA-G 14 bp ins/del genotype predisposes to
preeclampsia in the mother (Table 1). One study found an asso-
ciation between the 14 bp insertion allele in offspring from prim-
iparous preeclamptic women and controls (76, 103), which was
supported by another study that further demonstrated a reduced
level of the G3 isoform in placentas homozygous for the inser-
tion in mild preeclampsia (73). Conversely, other studies found
no association in offspring cases of preeclampsia, but notewor-
thy, included women with different degrees of preeclampsia (78,
104, 105). The discrepant results from different studies leave the
influence of the fetal 14 bp ins/del genotype on the risk of devel-
oping preeclampsia controversial. However, published studies are
characterized by small sample sizes, and larger scale studies are
necessary. Furthermore, assessing combined mother–child HLA-
G genotypes may be a better approach. The above mentioned
case-control study of 155 family triads of mother, father, and off-
spring performed by Hylenius et al. showed an association of
homozygosity for the 14 bp ins allele in offspring from primi-
parous women with severe preeclampsia (103), also supported
by others (104, 106). Furthermore, the results suggested that a
14 bp ins/del contribution from the father influenced the risk of
developing preeclampsia (103).
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Subject Association with preeclampsia
14bp ins/del polymorphism
Bermingham et al. (105) 68/74 Primiparous: all Parents and offspring No
O’Brien et al. (73) 7/11 ND Offspring Yes
Hylenius et al. (103) 57/98 Primiparous: 40/70
Multiparous: 17/28
Parents and offspring Yes. Association in offspring and in
mother/offspring pairs. Association with
paternal inheritance (only significant in
primiparous cases)
Vianna et al. (77) 157/162 ND Mothers No. A trend showing higher allele frequency
of 14 bp del in mothers with preeclampsia
Moreau et al. (74) 36/60 ND Offspring Yes
Iversen et al. (78) 31/43 ND Mothers and offspring No
Zhang et al. (106) 120/158;
82/87; 67/75
ND Mothers and offspring;
parents; fathers and offspring
Yes. Association in offspring, in
mother/offspring pairs and father/offspring
pairs
+3187 polymphism
Yie et al. (75) 29/15 Nulliparous Offspring Yes
G*01:04:xx
Carreiras et al. (207) 104/29 ND Mothers and offspring Partly, when the allele was maternally
inherited
Hylenius et al. (103) 57/98 Primiparous: 40/70 Parents and offspring No
Multiparous: 17/28
G*01:05N
Aldrich et al. (79) 57/36 ND Offspring No
Hylenius et al. (103) 57/98 Primiparous: 40/70 Parents and offspring No
Multiparous: 17/28
Loisel et al. (111) 58/314 ND Mothers Yes
G*01:06
Moreau et al. (74) 36/60 ND Offspring Yes
Tan et al. (104) 83/240 Primigravidas: 20/92 Mothers and offspring Yes. Also when paternally inherited
(multiparous women)Multigravidas: 63/148
ND, not determined/not described.
A puzzling thing about the 14 bp ins/del polymorphism is the
controversy about the abundance, and possibly, stability of the two
alleles. In fact, as stated earlier, the mRNA deletion transcript has
been shown to be more abundant than the mRNA insertion tran-
script. This fits well with studies showing higher sHLA-G levels
when homozygous for the deletion, and importantly, with studies
that support an association between the insertion allele, reduced
HLA-G levels and preeclampsia (72, 88). A mechanism that might
be compensatory to the lower HLA-G protein expression associ-
ated with the insertion allele exists: the presence of an alternative
splice transcript produced from, and secondary to, the 14 bp inser-
tion mRNA transcript. An in vitro study inducing a transcriptional
stop with Actinomycin D treatment in JEG-3 and M8 cell lines,
showed that the alternate transcript, characterized by removal of
92 bases from the insertion transcript, is more stable than the
14 bp insertion transcript (96). However, the−92 bp variant does
not represent the majority of transcripts (88, 96), and its physio-
logical relevance in vivo remains to be investigated. Complicating
the matter of linking differential HLA-G protein expression to
either the insertion or deletion mRNA transcripts, a recent study
using a K562 cell line transfected with the insertion and deletion
sequences separately, reported that membrane-bound HLA-G was
higher in insertion transfectants, while sHLA-G was lower (98).
Although these findings need verification, the study by Svend-
sen et al. indicates that the 14 bp ins/del genotype could have
an impact on the soluble/membrane-bound HLA-G ratio, and
could help clarify some of the conflicting results from preeclamp-
sia studies. As a highly debatable explanation to the findings by
Svendsen et al., ins/del HLA-G mRNA transcripts could have dif-
ferent structural features of the untranslated regions and coding
sequences – a major and overlooked part in the control of mRNA
translation. Relaxed secondary structures in UTRs are common
for many mRNAs and characterize transcripts that are translated
at a high rate (107). Conversely, more stable mRNA secondary
structures containing e.g., hairpin loops, although exhibiting low
turnover of mRNA, may be translated at a slower rate (107). The
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secondary structures of the 14 bp ins/del mRNA transcripts have
not been elucidated, but potential differences could explain why
the insertion allele, albeit less abundant, is associated with high
membrane-bound HLA-G. It does not, however, explain the lower
sHLA-G levels associated with the insertion allele, which could be
related to differences in the dynamics of HLA-G translation and
post-translational mechanisms, e.g., shedding of HLA-G1 from
the cell surface.
Several HLA-G SNPs are shown to be in strong linkage dise-
quilibrium with the 14 bp ins/del polymorphism. These include
a −725 SNP located in the promoter region previously shown to
affect the transcriptional rates of HLA-G (108), and an array of
SNPs in the 3′UTR downstream from the 14 bp ins/del that may
act as microRNA sites and influence mRNA size and stability (109,
110). These include SNPs at+3142,+3187, and+3196 (109). Yie
et al. reported that the+3187 SNP was associated with differences
in mRNA stability, and that homozygous offspring were strongly
correlated with severe preeclampsia (75). An association between
HLA-G haplotypes and preeclampsia has been reported in some
studies (76) but not in all (111). In the study by Larsen et al., a
fetal HLA-G 3′UTR haplotype consisting of the 14 bp insertion
sequence, a C at the+3010 SNP, a G at the+3142 SNP, an A at the
+3187 SNP, and a G at the+3196 SNP was associated with the risk
of developing severe preeclampsia in primipara (76). Interestingly,
another fetal HLA-G 3′UTR haplotype with the 14 bp deletion, a
G at the +3010 SNP, a C at the +3142 SNP, an A at the +3187
SNP, and a C at the +3196 SNP was much more frequent in the
control group of primipara with no preeclampsia compared to the
primipara group with severe preeclampsia (26.4% vs. 6.3%).
An HLA-G allele containing the 14 bp insertion, G*01:06, has
been linked to preeclampsia in different studies [(74, 103, 104)].
The polymorphic 1 bp deletion of a cytosine residue at codon
130 which results in null allele (G*01:05N) described earlier, is
associated with increased risk of preeclampsia in one study (111),
and a reduced HLA-G level in maternal serum from normoten-
sive African-American controls was observed in women bearing
the null allele (111). However, this was not confirmed in another
study (79). The 1597∆C null mutation is rare in Europeans but
more common in other global populations (79, 102, 112, 113),
which emphasizes that ethnic difference or demographic factors
should be considered in future study set-up, or when interpreting
meta-studies on the association of HLA-G polymorphisms with
preeclampsia.
Taken together, whether HLA-G genotypes and expression pat-
terns might have a significant influence on the development of
preeclampsia remains controversial. Further studies investigat-
ing an array of polymorphisms associated with preeclampsia in
a larger scale are warranted, especially ones that set to investigate
the mRNA and cell surface protein expressions simultaneously.
HLA-E ALLELIC POLYMORPHISMS
Two non-synonymous HLA-E alleles, E*01:01:xx:xx and
E*01:03:xx:xx, have been identified (36, 114). They are distin-
guished by having either an arginine or a glycine at position 107
of the protein, and are so far the only HLA-E allelic variants to
affect intracellular trafficking and surface expression (115). The
frequency of these alleles is nearly equal in different populations,
which indicates a balancing selection implying that a functional
difference exists between the two alleles (116). One study showed
that, although no difference was found between proteins in steady-
state, the E*01:03:xx:xx allele exhibited higher surface expression
than the E*01:01:xx:xx allele (117). In addition, the E*01:01:xx:xx
and E*01:03:xx:xx alleles differ in their peptide binding affini-
ties, E*01:03:xx:xx exhibiting a 10- to 100-fold higher affinity
than E*01:01:xx:xx. A differential expression could have conse-
quences for the inhibitory effect of HLA-E on NK cells and T cells.
Indeed, the surface levels of HLA-E have been shown to affect
inhibitory activity in vitro (22), and HLA-E polymorphisms have
been associated with nasopharyngeal carcinoma (118), and recur-
rent spontaneous abortions (119). If HLA-E expression is hypoth-
esized to be important in the context of pregnancy, an association
of preeclampsia with HLA-E polymorphisms seems relevant to
investigate. While no such study exists, one study showed that sera
from early-onset, severe preeclamptic women could induce HLA-
E surface expression in an EA.hy296 endothelial cell line in vitro
(120). This upregulation was countered by addition of recombi-
nant interferon (IFN)-γ. Soluble HLA-E was detectable in sera,
but no difference was found between preeclamptic women and
controls (120), indicating HLA-E surface expression on endothe-
lial cells as a symptom of endothelial activation in preeclampsia,
possibly mediated by other factors.
PATERNAL CONTRIBUTION TO PREECLAMPSIA
Preeclampsia is mostly considered a disease with maternal and
fetal involvement, but there are some indications of paternal con-
tributions as well. For example, preeclampsia is associated with
an increased partner-specific CTL response in a mixed lympho-
cyte reaction (MLR), a finding that was not observed, when the
MLR was performed with an unrelated partner, who fathered two
previous uncomplicated pregnancies (121). This study indicates
a maternal response directed against specific paternal antigens.
In addition, the fetus is a natural allograft and the mother could
carry killer immunoglobulin-like (KIR) allelic gene variants that
mismatch with paternal HLA-C expressed on trophoblast cells.
KIR receptors constitutes a highly polymorphic family of HLA
class I receptors expressed on NK cells that is able to engage a
cytotoxic NK cell response upon binding to HLA-C in the pla-
centa. One study found that the combination of maternal KIR-AA
and fetal HLA-C2, but not fetal HLA-C1, lead to increased risk of
preeclampsia (122), but more studies are needed to confirm this.
A paternal contribution of the G*01:06 allele increases the risk
of preeclampsia in multigravidae, at least according to one study
(104). In the case-control study using family triads by Hylenius
et al., an importance of paternal transmission of the 14 bp ins HLA-
G allele to the offspring in the preeclampsia triads was observed,
which supports the findings by Tan et al. (103). Another triad-
study found that father/offspring pairs homozygous for the 14 bp
del were significantly less frequent in early- compared to late-onset
preeclampsia (106).
IMMUNE CELLS IN PREGNANCY AND PREECLAMPSIA
Initially, data from epidemiologic studies suggested that inappro-
priate activation of the immune system or immune maladaptation
plays a critical role in the development of preeclampsia (123). Ex

























































Djurisic and Hviid HLA-G and immune cells in preeclampsia
vivo studies have since confirmed that immune cells play a central
role in the pathophysiology of preeclampsia (124). An emerging
theory is that a shift in immune cell functionality in uterine sub-
populations reflects a maladapted maternal immune system, or
a loss of tolerance mechanisms, which precedes the progress of
placental oxidative stress and ischemia observed in preeclamp-
sia (Figure 3) (125). Uncomplicated pregnancies are dependent
on a delicate interplay between regulatory T cells and dNK cells
that recognize and accept paternal antigens presented by the semi-
allogenic fetus while simultaneously allowing vascular remodeling
and placental growth (3). Although regulatory T cells and dNK
cells have been the focus of most studies, it is likely that other
immune cells like monocytes, DCs, and macrophages participate
in upholding fetal tolerance (Figure 3). An aberrant/activated
maternal immune system is associated with pregnancy complica-
tions like recurrent spontaneous abortions and preeclampsia. The
expression of HLA-G receptors on decidual immune populations
like NK cells, T cells, DCs, monocytes, and macrophages implicate
HLA-G in the regulation of the uterine microenvironment (126,
127). However, direct effects of HLA-G on immune cell activation,
recruitment, and function in the context of preeclampsia remain
to be elucidated.
NK CELLS IN PREGNANCY AND PREECLAMPSIA
The early decidua is characterized by a unique population of
dNK cells that constitute 50–90% of all leukocytes present in
the uterine compartment in first trimester (1, 128). Compared
to conventional pNK cells circulating the periphery, dNK cells
exhibit a different repertoire of cytokines and receptors reflect-
ing a more tissue-specific function (128, 129). dNK cells secrete
vascular endothelial growth factor (VEGF), placental growth fac-
tor (PLGF), interleukin-8 (IL-8), and IFN-inducible protein-10
(IP-10) (129). In an in vitro migratory assay, dNK cell migration
was correlated to the amount of the chemokines IL-8 and IP-10,
when co-cultured with trophoblast cells (129), indicating a specific
recruitment possibly mediated by the cognate CXCR1 and CXR3
chemokine receptors expressed on trophoblast cells. An aberrant
production of cytokines and chemokines could have a great impact
on the depth of trophoblast infiltration/invasion as seen in cases
of preeclampsia.
In preeclampsia, pNK cells have en altered NKG2A and -C
receptor expression (130), while dNK cells isolated from decidua
at term show a higher expression of NKG2-associated receptor
CD94 (131). HLA-G interacts with three inhibitory receptors,
ILT2, ILT4, and KIR2DL4, as discussed earlier (132, 133). KIR2DL4
is not expressed on the surface of NK cells in steady-state, but
surface expression can be induced after in vitro culture, and
the expression and function is determined by genotype (134).
KIR2DL4 seems not to be associated with preeclampsia. How-
ever, the presence of a fetal G*01:06 allele in combination with the
maternal KIR2DL4*006 allele has been reported to be significantly
associated with preeclampsia risk in multigravida pregnancies,
suggesting a gene–gene interaction (135).
A recent study showed that a decidual population of
CD56highCD27+ dNK cells accumulates in the first trimester
of pregnancy and dampens the effects of inflammatory Th17
cells via IFN-γ secretion (136). In an Nfil3−/− mouse model of
pregnancy where the mice lack NK cells entirely, and in an NK
cell-depleted pregnant mouse group, they both demonstrated a
significantly higher percentage of Th17 cells (136). In humans,
the CD56highCD27+ dNK cells and their supernatants inhibited
the expansion of Th17 cells – an effect reversed by addition of
neutralizing anti-INF-γ (136).
There is still some controversy about NK numbers in
preeclampsia. In peripheral blood, the prevalence of NK cells differ
between preeclamptic cases and controls in some studies (137) but
not in all (138). However, it is more likely that a difference should
be found in the uterine environment within the dNK population.
HLA-G has been shown to inhibit NK lysis in HLA-G transfected
cell lines in a concentration-dependent manner (91, 139, 140),
and the physiological relevance of this effect was demonstrated
by a study showing that ex vivo NK cell functional responses to
HLA-G differ between peripheral blood and decidua, where dNK
cells were refractory to stimulation compared to pNK cells (141),
further supporting the important role of HLA-G in sustaining
pregnancy and its influence on dNK cells.
T CELLS IN PREGNANCY AND PREECLAMPSIA
CD4+ T cells, or T helper (Th) cells, can be subgrouped on the
basis of their cytokine profile into Th1 and Th2 T cells. According
to an early theory, successful pregnancy is biased toward a Th2
humoral response characterized by release of immunoregulatory
cytokines such as IL-10 and TGF-β (142). Cytokines and other
soluble factors like progesterone and indoleamine 2,3-dioxygenase
(IDO) have been proposed to act on the Th1/Th2 balance, and a
shift toward a Th1 response has been hypothesized to occur in
preeclampsia (143). Furthermore, when cell lines are transfected
with membrane-bound HLA-G1 and co-cultured with decidual or
uterine mononuclear cells, several studies have observed a decrease
in TNF-α and an increase in IL-10 (144–146). So, it seems plausi-
ble that HLA-G can mediate a shift from a proinflammatory Th1
cell-mediated response toward a Th2 response inducing tolerance.
However, pregnancies in Th2 knockout mice proceed without
complications, indicating how a higher complexity of the cytokine
network in the placenta or other mechanisms may add to fetal tol-
erance (147). In the slipstream of the Th1/Th2 paradigm, a new
has emerged: the Th1/Th2/Th17/T regulatory cells (Tregs) par-
adigm (148). Th17 cells are immunoregulatory cells that play a
critical role in induction of inflammation and have been linked to
autoimmune diseases and tissue transplant rejection, and possibly
to pregnancy complications (148, 149). The Th1/Th2 balance and
the capacity of Th17 cells to produce cytokines are modulated by
TGF-β and IL-10 or by cell–cell interaction with CD4+CD25high
Tregs, described later (148). Although little is known about Th17
cells, recruitment and expansion of this subset seem to be pro-
moted by proinflammatory cytokines like IL-1β and IL-6, and
the highest percentage exists in the first trimester (136, 150).
Interestingly, a novel role for Th17 cells in trophoblast prolif-
eration and invasion was recently indicated (151). In this study,
Th17 cells were recruited from the periphery in early pregnancy
by CCL2-secreting decidual stromal cells, and inhibited apopto-
sis of trophoblast cells via an IL-17-dependant mechanism (151),
suggesting a vital role for Th17 cells in normal pregnancy. How-
ever, an exaggerated production of IL-17 could have unwarranted
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FIGURE 3 | Possible immune interactions between HLA-G and decidual
immune cells in normal pregnancy and in preeclampsia. (A) In normal
pregnancy, HLA-G expression is believed to ensure a tolerogenic uterine
environment by inhibiting cytotoxicity, inducing release of anti-inflammatory
cytokines, and by promoting proliferation of tolerogenic decidual immune
cells that mutually stimulate each other to sustain tolerance. (B) In
preeclampsia, a possible reduced soluble and membrane-bound HLA-G
expression in trophoblast cells may affect immune cells expressing cognate
receptors, and thus enhance immunity rather than tolerance. Increased CCL2
and CCL5 chemokines and inflammatory cytokines may recruit activated
immune cells from the periphery further abrogating the tolerogenic milieu.
Dotted lines represent reduced stimuli.
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consequences. In preeclampsia, the prevalence of IL-17-producing
CD4, CD8, and NK cells is elevated in peripheral blood compared
with normotensive pregnant women (152), and the Th1/Th2 and
Th17/Treg balance is shifted toward increased immunity deter-
mined by a Th1 response, elevated Th17 T cells and reduced
Treg numbers, possibly affecting the uterine microenvironment
conjointly with dNK cells (152). Furthermore, in preeclampsia,
monocytes produce IL-1β and IL-6 that mediate terminal differen-
tiation of Th17 cells possibly causing an exaggerated inflammatory
response, which may consequently reduce Treg abundance and
function (148).
Classical Tregs constitute a subset of T cells with suppressive
properties. They are capable of inhibiting redundant immune
responses in a very potent fashion, and aid in maintaining antigen-
specific T cell tolerance important in pregnancy (153). In mice, the
Treg population increases markedly during early gestation (154),
and a similar effect is observed in pregnant women with a peak
during the second trimester and a decline in numbers postpar-
tum (155). Adoptive transfer studies in mice have demonstrated
the physiological importance of CD4+CD25+ Tregs in pregnancy
(156, 157). For example, when a total pool of CD4+ T cells
is depleted of the CD4+CD25+ Treg subpopulation and trans-
ferred into pregnant mice deficient of T cells, allogeneic mice
fetuses are rejected, while syngeneic fetuses remain unaffected
(156). In humans, isolated CD4+CD25+ cells are able to sup-
press autologous CD4+ T cells stimulated by allogeneic DCs (155),
and to inhibit IL-4 secretion against paternal but not unrelated
allo-antigens in vitro (158).
In preeclampsia, the number of CD4+CD25high Tregs is
decreased in peripheral blood (150, 159) as well as in term pla-
centas (160). However, not all studies confirm these findings
(161). Assessing Treg numbers based on the co-expression of CD4
and CD25 solely has been questioned, and with the identifica-
tion of the transcription factor forkhead box P3 (Foxp3), a more
reliable marker for Tregs was found. In support of the findings
associating CD4+CD25high Treg numbers with preeclampsia, cir-
culating levels of CD4+CD25highFoxP3+ Tregs are decreased in
preeclamptic women (138, 150, 162). Highly relevant in the con-
text of identifying Tregs, a study by Santner-Nanan et al. compared
CD4+CD25high, CD4+CD127lowCD25+, and CD4+Foxp3+ cells
from preeclamptic women and controls, and found that the fre-
quency of Tregs in all three “groups” was reduced in preeclamptic
women (150). However, ex vivo-sorted Tregs had preserved their
suppressive properties implying that a reduced number of Tregs
rather than a lack of suppressive function occurs in preeclampsia
(150). Furthermore, Santner-Nanan et al. also reported that the
ratio of Tregs to Th17 was significantly increased in normal preg-
nancy but not in preeclampsia (150). The conversion of Tregs to
Th cells has been documented in both mice and humans (163),
and lately, this conversion has been suggested to occur as a part of
the pathophysiology of preeclampsia (164).
Subsets of non-conventional Tregs more recently described
include HLA-G-positive Tregs and tolerogenic CD4low and CD8low
T cells. CD4+HLA-G+ Tregs lack classical Treg markers and are
characterized by the constitutive expression of HLA-G (165).
Functional characterization indicates that the suppressive prop-
erties of this subset rely on the immunoregulatory properties of
HLA-G, which enables CD4+HLA-G+ Tregs to inhibit bystander
immune activations by direct cell–cell interaction (166). In normal
pregnancy, the prevalence of CD4+HLA-G+ T cells is high in
decidua (167), while a recent study showed that the expansion
of the HLA-G-positive T cell subset is impaired in preeclampsia
(168). Furthermore, it was indicated that classical Foxp3 Tregs and
CD4+ T cells acquire HLA-G from monocyte-derived DCs via
the process of trogocytosis where membrane fragments are dis-
patched from the DCs and transferred to the surface membrane
of leukocytes (168).
Non-conventional regulatory T cell subsets, which are distin-
guished by lower surface expression of CD4 and CD8, have been
identified in a transplantation study (169). Interestingly, regu-
latory activity by these CD3+CD4low and CD3+CD8low T cells
was induced by soluble HLA-G and/or HLA-G1-expressing DCs
(169). While these subsets have not been investigated in relation to
pregnancy and preeclampsia, it is reasonable to believe that their
suppressive activities mediating allograft acceptance could be rele-
vant in a pregnancy setting, and match a hypothesis where HLA-G
in the placental microenvironment influences the phenotype and
function of local T cells.
B CELLS IN PREGNANCY AND PREECLAMPSIA
In normal pregnancy, the almost complete absence of B cells in
decidua suggests that no B cells are localized, recruited nor acti-
vated by fetal allo-antigens (170). Like for other leukocytes, ILT2
is also expressed on the surface of B cells (133). A recent study
in mice showed that ILT2–HLA-G engagement on B cells inhibits
both naïve and memory B cell function in vivo and in vitro at the
level of proliferation, differentiation, and Ig secretion (171). The
inhibitory effects of HLA-G were independent of the form of B
cell activation, suggesting that the presence of T cells could be less
important. Moreover, HLA-G mediates phenotypic and functional
downregulation of CXCR4 and CXCR5 chemokine receptors on
germinal center B cells (171). In vivo support for HLA-G as a neg-
ative B cell regulator was provided in a xenograft mouse model,
which showed a significantly altered antibody secretion pattern
(171).
A specific subpopulation of CD19+CD5+ B cells that secrete
autoantibodies is identified in preeclampsia (172), indicating a
dysfunctional immune regulation or B cell activation mediated
by fetal allo-antibodies. Furthermore, a recent study on the inter-
actions between Tregs and B cells indicated that a negative cor-
relation between Tregs and memory B cells exists in peripheral
blood of preeclamptic women (173). Although the Treg popula-
tion was reduced numerically, interestingly, the suppressive effects
on autologous B cell proliferation were unaffected (173).
DCs ANDMONOCYTES IN PREGNANCY AND PREECLAMPSIA
In the periphery, DCs play a crucial role in linking innate and adap-
tive immunity by virtue of their exceptional ability to capture,
process and present antigens to naïve T cells, and by mediating
cross-talk with a broad range of immune cells. In the decidua,
however, DCs are scarce, making up app. 1% of the decidual
immune population (174). A decidual subset of tolerogenic DCs
that express high levels of HLA-G was recently identified. These
cells spontaneously secrete high amounts of IL-10 and are named
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DC-10. DC-10s can be differentiated in vitro from peripheral
blood monocytes with proinflammatory cytokines including gran-
ulocyte macrophage-colony stimulating factor (GM-CSF), IL-4,
and IL-10 (175, 176). DC-10s are able to induce immunosuppres-
sive CD4+ T cells, and their potency to do so was demonstrated
when a single stimulation of CD4+ T cells with DC-10 pro-
moted a fraction of anergic T cells that contained up to 15% of
already differentiated inducible Tregs (177, 178). In a transplan-
tation study, engagement of ILT4 on DCs by HLA-G-tetramers
resulted in maturation/activation, and prolongation of allogeneic
graft survival (179). The local milieu in the placenta is likely to
moderate the function and activity of local immune cells, but
evidence points to a systemic effect as well. As an example, the
TLR expression and cytokine profile in circulating DCs is dysreg-
ulated in preeclampsia, and they demonstrate a weaker response
to TLR-stimulation compared with controls (180). In addition,
a recruitment of mature and immature DCs to the decidua is
observed in preeclampsia (181).
MACROPHAGES IN PREGNANCY AND PREECLAMPSIA
The majority of decidual leukocytes in the first trimester con-
sist of NK cells and second to these are the tissue-specific
macrophages, which make up 20–25% (1, 182, 183). These decid-
ual macrophages are characterized by their immunosuppressive
abilities, and two different subsets have so far been identified
in the feto-maternal interface; single-positive CD14−CD68+ and
double-positive CD14+CD68+ macrophages (183, 184), which,
however, still need to be characterized. The abundance of decidual
macrophages in the first trimester indicates vital tissue-specific
functions and thus, an important role in maintenance of nor-
mal pregnancy (185). In support of this notion, they are co-
localized with evading trophoblast cells and found in the vicin-
ity of spiral arteries, where they are believed to modulate the
immune response to pathogens, to mediate vascular remodeling
and promote trophoblast invasion (186, 187).
Studies have shown that decidual macrophages may con-
tribute to the development of preeclampsia, primarily by a shift
in the cytokine profile leading to poor spiral artery remodel-
ing (186, 188, 189). In addition, increased macrophage infiltra-
tion in the decidua is observed in preeclampsia (181). Upon
proinflammatory stimuli, monocytes, macrophages, and DCs are
recruited to the decidua by specific chemokines, especially CCL2
and CCL5 (190). In accordance with the observed increase in
infiltration of macrophages in preeclampsia, CCL2 and CCL5
expression is increased in preeclamptic decidua (181). An exces-
sive release of GM-CSF in preeclamptic placentas contributes
to macrophage differentiation, further increasing the produc-
tion of proinflammatory cytokines (191). TNF-α, PAI-1, and
inducible nitric oxide synthase secreted by decidual macrophages
inhibit trophoblast invasion and migration, and thus, spiral
artery remodeling (192, 193). Macrophages regulate angiogene-
sis by secreting VEGF, which binds to fms-like tyrosine kinase-1
(Flt-1), both of which are dysregulated in preeclampsia (194).
In addition, decidual macrophages express IL-2 and ILT4, and
HLA-G may thus regulate their functional properties (82, 133).
This was indicated in a study showing that upon co-culture
with transfectants expressing HLA-G homodimers, cytokine
production was greatly increased in CD14-positive decidual
macrophages (195).
Similar to the concept of Th1/Th2 polarization in effector T
cell function, macrophages are characterized according to their
effector phenotype and cytokine repertoire, subgrouping them
into classical activated macrophages, M1, or alternatively activated
macrophages, M2 (185, 196). M1 secretes IL-12 and TNF-α upon
stimuli from LPS or IFN-γ, while M2 upon stimuli with IL-4
secretes the tolerogenic cytokines IL-10 and IL-13 (196). How-
ever, the existence of a M1/M2 balance in the placenta and the
possible implication of this in preeclampsia still need to be inves-
tigated. Recently, increased numbers of CD14+ cells were iden-
tified in preterm preeclamptic placentaes, and – supporting the
importance of a M1/M2 balance – a lower CD163+/CD14+ ratio
(M2), and a higher CD209+/CD14+ ratio (M1) were observed in
preeclamptic placentas compared with controls (197).
CONCLUSION AND PERSPECTIVES
A vast amount of evidence highpoint an involvement of immune
cell populations in pregnancy, and preeclampsia is indeed charac-
terized by an aberrant immune system. While studies show that a
broad continuum of immune cells are affected, or more specifically
activated, to induce unwanted immunity rather than tolerance
against the semi-allogeneic fetus in preeclampsia (123, 125), an
important question is whether this occurrence precedes the abro-
gated placentation and endothelial activation and inflammation
observed. Associations between cytokine production and reper-
toire and vascularization support this theory. Given that immune
maladaptation is an early event in the etiology of preeclampsia,
we speculate whether one or few immune populations are respon-
sible for altering the local, and possibly systemic, cytokine milieu
resulting in a more general change in the function and abundance
of other immune cells not typically present in the uterine envi-
ronment – like B cells and DCs. This would require an immune
population that acts as a “linker” between the innate and adaptive
immune system, and in addition, an immune population with spe-
cific receptors for HLA class Ib expressed by trophoblast cells. A
simple answer would be that the dNK cells constitute this “linker”
population. However, the explanation may not be that straight-
forward. Transplantation studies have offered new insights into
tolerance mechanisms provided by other immune cells. These
include tolerogenic CD4low and CD8low T cells, HLA-G-expressing
T cells and HLA-G-expressing DCs, and in this context, the key
perspective may not be abundance, since these cells are present in
low numbers, but instead tolerance potency.
Immunological memory is another important aspect that needs
to be addressed. According to epidemiological findings, primipar-
ity is the strongest risk factor for preeclampsia occurring in up to
75% of cases (123, 198, 199). Furthermore, in multiparas, a change
of partner increases the risk to the level of the first pregnancy,
although the idea of a partner-specific effect has been challenged
as merely a consequence of a long interval since the last pregnancy,
which is also a risk factor of preeclampsia (123, 200). Memory T
cells, which induce tolerance to paternal antigens, may explain
these epidemiological findings (123, 201). In mice, an accelerated
expansion of maternal CD4+Foxp3+ Tregs specific for fetal anti-
gens support that multiparas are protected by a regulatory memory
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for fetal antigens (201, 202). Recent data have also revealed that
exposure to seminal fluid may induce paternal-specific tolerance
(203) and short cohabitation, use of condoms and insemination
with donated spermatozoa are risk factors of preeclampsia (123)
suggesting that absence of semen exposure could fail to induce ade-
quate tolerance, resulting in preeclampsia. Paternal allo-antigens
and soluble factors like TGF-β, prostaglandins and HLA-G are
present in seminal fluid, and could well prove important for Treg
expansion, differentiation, and immunological memory (42, 203,
204).
While some decidual cell populations, including Tregs and
DC-10, may be licensed for tolerance induction or immune mod-
ulation even before conception, it is likely that their differentiation
and proliferation is co-dependent on the HLA class Ib molecules
both in the initial stages and throughout the course of preg-
nancy. Indeed, reviewing the idea that a “linker” is needed to
affect vascularization and different immune populations simul-
taneously, and given that aberrant dNK function and numbers
are not sufficient to account for the pathophysiology observed in
preeclampsia alone, this “linker” may well be represented by HLA-
G. The low expression of HLA-G in preeclampsia, and the sum of
in vivo and in vitro studies showing a broad array of immune
interactions/cross-talk with, and through, HLA-G and cognate
receptors, supports this hypothesis. Why is it then that genetic vari-
ation in HLA-G, although nicely shown to influence the transcrip-
tion and expression of HLA-G in vitro still lacks strong association
with preeclampsia in some studies? One answer could be that we
still lack knowledge of some fundamental aspects of HLA-G biol-
ogy. What significance can be attributed the alternative splicing
of HLA-G mRNA transcripts, and what are their isoform-specific
functions? What is the significance of higher-order HLA-G- and
HLA class Ib protein-assemblies and HLA-G-positive exosomes,
and are they detected with conventional assays? These questions
have not been actively addressed so far, and some investigators
have indicated that due to the low abundance of G2 and G4-7
mRNA transcripts in the placenta, the physiological effects are
provided essentially by HLA-G1 (89, 205). Conflicting with this
notion is the immune regulatory capacity of the HLA-G5 isoform
that, despite the fact that this transcript is scant in the placenta, has
proven potent as an immunosupressor in several studies (59, 87).
Another explanation for the lack of association between HLA-G
genetics and preeclampsia could be due to different methodologi-
cal approaches, small-scale studies on different ethnic populations,
or explained by the fact that preeclampsia is a multifactorial disease
that presents with different degrees of severity, and additionally,
in an early- and late-onset form, possibly with distinct etiologies
(206).
The involvement of HLA class Ib in preeclampsia remains
controversial. The function of HLA-F is unknown, and despite
findings showing that HLA-E is involved in immune suppres-
sion, soluble HLA-E levels seem not associated with preeclampsia.
More studies, not only focusing on the two non-synonymous
alleles classically investigated, are needed. The functional sig-
nificance of HLA-G in pregnancy is more complex than HLA-
E and -F. However, the high expression of HLA-G compared
to HLA-E and -F in the placenta, and the presence of HLA-
G in semen, the endometrium, in the matured cumulus–oocyte
complex, as well as the rise in soluble level after conception imply
an important role for HLA-G in early pregnancy (42, 45). Further-
more, the dual role of HLA-G in immune regulation and spiral
artery remodeling underscores its importance and multifaceted
activities. So far, aberrant HLA-G expression is a likely contribu-
tion to preeclampsia. As isoform-specific functions are possible to
exist, more studies on this are highly warranted.
The etiology of preeclampsia is multifactorial and involves
interactions between immune cells and HLA class Ib molecules,
possibly as early as during conception or embryogenesis (46). And
since an interaction in essence is a mutual or reciprocal action or
influence, any one unfavorable genetic or immunological contri-
bution either from the mother, the father, or the fetus, may tip the
steady-state immune balance in a direction unfavorable for preg-
nancy – consequently leading to preeclampsia. Further in-depth
investigation will help to elucidate the precise mechanism of HLA
class Ib receptor recognition and signaling, and the role of these
interactions in successful reproduction.
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